Making Healthy Stem Cells: The New Role of TPO  by Goyama, Susumu & Mulloy, James C.
Cell Stem Cell
In TranslationNishimura, T., Kaneko, S., Kawana-Tachikawa, A.,
Tajima, Y., Gotoh, H., Zhu, D., Nakayama, K.,
Iriguchi, S., Uemura, Y., Shimizu, T., et al. (2013).
Cell Stem Cell 12, this issue, 114–126.
Restifo, N.P., Dudley, M.E., and Rosenberg, S.A.
(2012). Nat. Rev. Immunol. 12, 269–281.8 Cell Stem Cell 12, January 3, 2013 ª2013 ERosenberg, S.A. (2011). Nat Rev Clin Oncol 8,
577–585.
Schmitt, T.M., and Zu´n˜iga-Pflu¨cker, J.C. (2002).
Immunity 17, 749–756.
Takahashi, K., and Yamanaka, S. (2006). Cell 126,
663–676.lsevier Inc.Vizcardo, R., Masuda, K., Yamada, D., Ikawa, T.,
Shimizu, K., Fujii, S.-i., Koseki, H., Kawamoto,
H., et al. (2013). Cell Stem Cell 12, this issue,
31–36.
Wu, S.M., and Hochedlinger, K. (2011). Nat. Cell
Biol. 13, 497–505.Making Healthy Stem Cells: The New Role of TPOSusumu Goyama1 and James C. Mulloy1,*
1Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
*Correspondence: james.mulloy@cchmc.org
http://dx.doi.org/10.1016/j.stem.2012.12.008
Thrombopoietin (TPO) attracts much attention as an effective stimulus for blood cell formation in patients
with hematopoietic disorders. In this issue of Cell Stem Cell, de Laval et al. (2013) show that TPO can also
promote ‘‘healthy’’ hematopoietic stem cells when administered before radiotherapy to minimize HSC injury
and mutagenesis in mice.Thrombopoietin (TPO) has a well-de-
scribed role as a principal regulator of
platelet production, which is stimulated
through binding to its receptor Mpl on
megakaryocytes. More recently, studies
have revealed important roles for TPO/
Mpl signaling in hematopoietic stem cells
(HSCs) as well (reviewed in Chou and
Mulloy, 2011). Mpl is expressed in HSCs
and progenitors, and TPO cooperates
with other cytokines to promote expan-
sion of HSCs in culture. Mice deficient
in TPO and Mpl signaling have reduced
numbers of HSCs with impaired repopu-
lating ability as well as the defective
platelet formation one would expect.
Clinically, inactivating mutations of Mpl
in humans cause thrombocytopenia and
multilineage marrow failure, while acti-
vating Mpl mutations are involved in
myeloproliferative disorders. These ob-
servations demonstrate an important
role of TPO/Mpl signaling in HSCs and
progenitors. As a mechanism for TPO-
mediated HSC regulation, it was shown
that TPO regulates HSC quiescence and
interaction with the osteoblastic niche
(Qian et al., 2007; Yoshihara et al., 2007).
Cells in the human body are continually
exposed to DNA stresses. Physiological
stresses as well as environmental
agents, such as ionizing radiation (IR)
and other genotoxic chemicals, induceDNA damage including double-strand
breaks (DSBs). DNA repair is essential
for cell survival, and the long lifespan of
HSCs suggests that they need an effec-
tive DNA repair process to maintain a
‘‘healthy’’ state. DNA damage is repaired
through two main pathways: homologous
recombination (HR) and nonhomolo-
gous end joining (NHEJ). Recent data
showed that quiescent HSCs preferen-
tially use NHEJ repair mechanism, and
DSB repair through NHEJ is necessary
for HSC maintenance (Mohrin et al.,
2010; Nijnik et al., 2007; Rossi et al.,
2007).
In this issue of Cell Stem Cell, de Laval
et al. (2013) discovered a new function
of TPO in DNA damage response in
HSCs and progenitors. They found that
Mpl-deficient HSCs and progenitors
had significantly increased numbers of
gH2AX foci (a marker of DSB formation)
after exposure to IR or topoisomerase-II
inhibitors relative to wild-type cells. A
neutral comet assay (another technique
for the detection of DSBs) also showed
IR-induced DNA damage was greatly
enhanced in Mpl-deficient cells. Consis-
tent with these findings, HSCs treated in
the absence of TPO showed similar DSB
repair defects and, conversely, TPO injec-
tion into mice just before IR reduced the
number of gH2AX in HSCs in vivo. Nodifferences in cell cycle and apoptotic
status of HSCs were apparent under
these experimental settings, implying the
TPO/Mpl signaling was affecting DNA
damage in HSCs through a direct effect
on the DNA repair process. Other hema-
topoietic cytokines such as SCF and
FLT3 ligand did not show such effects,
suggesting that the DNA repair activity is
a specific function of TPO. de Laval et al.
(2013) found that TPO increased phos-
phorylation of the DNA-PK catalytic
subunit (a central player in NHEJ), and
pharmacological or genetic inhibition of
DNA-PK abolished TPO-mediated DNA
repair. TPO did not increase IR-induced
Rad51 foci formation nor did it improve
repair of DSBs induced by replicative
stress, indicating HR was not involved in
this DSB repair. Taken together, these
results indicate that TPO/Mpl promotes
NHEJ-mediated DNA repair by stimu-
lating DNA-PK activity in HSCs. Impor-
tantly, TPO treatment before IR limits
IR-induced HSC injury and increases
HSC function for long-term hematopoietic
reconstitution, raising the potential
clinical application of TPO agonists in
patients receiving radiotherapy or chemo-
therapy. The findings also imply that
agonists of TPO/mpl may be effective in
patients suffering from inefficient hemato-
poiesis caused by damaged HSCs.
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In TranslationMuch effort has been devoted to identi-
fying clinically useful drugs that mimic the
effects of TPO. After the cloning of human
TPO, two recombinant TPO molecules
were developed and tested in clinical
trials. These first-generation recombinant
TPOs showed clinical efficacy in treating
idiopathic thrombocytopenic purpura
(ITP) patients, platelet apheresis donors,
and patients receiving nonmyeloablative
chemotherapy. Unfortunately, the ap-
pearance of neutralizing antibodies to
some forms of recombinant TPO ended
these clinical efforts. Since then, a number
of nonimmunogenic second-generation
molecules have been developed, in-
cluding TPO peptide mimetics (e.g., romi-
plostim), TPO nonpeptide mimetics (e.g.,
eltrombopag), and TPO agonist anti-
bodies. Among these, romiplostim and
eltrombopag have shown impressive
clinical benefits, increasing the platelet
counts in >80% of ITP patients without
significant adverse effects (reviewed in
Kuter, 2007). More recently, eltrombopag
showed significant effects not only in
platelet but also in erythroid and neutro-
phil lineages in 44% of patients with
severe aplastic anemia (Olnes et al.,
2012). This observation suggests that
eltrombopag stimulates hematopoiesis
at the level of primitive HSCs, consistent
with the findings of de Laval et al. (2013)
showing that TPO increases HSC
function.
However, some concerns have arisen
regarding the clinical use of TPO
agonists. The experience of the first-
generation molecules suggested that
administration of recombinant TPO was
not effective in patients with high levels
of endogenous TPO, including those
receiving stem cell transplantation or
induction therapy for acute leukemia
(Kuter, 2007). Such predictions may not
be true for the TPO nonpeptide mimetics,
such as eltrombopag, because they bind
to Mpl in a region not occupied by TPO
and have an additive effect to that of
TPO. Indeed, patients with aplastic
anemia showed clinical response toeltrombopag despite their high levels of
endogenous TPO (Olnes et al., 2012).
Long-term administration of TPO may
cause several complications, including
thrombosis and bone marrow fibrosis.
Ongoing clinical studies should establish
the incidence of these complications.
Perhaps the most serious concern is
that enhanced TPO/mpl signaling can
promote clonal evolution toward leu-
kemia. In fact, progression from myelo-
dysplastic syndrome (MDS) to acute
myeloid leukemia has been observed in
a clinical trial of romiplostim, although it
is not yet clear whether the progression
rate is truly higher than expected.
Enhanced TPO/Mpl signaling has been
shown in many hematopoietic neo-
plasms, and the results of de Laval et al.
(2013) further indicate the possibility that
TPO could enhance the DNA repair in
leukemia stem cells to promote leukemia
progression. Thus, caution is required
when TPO mimetics are used for MDS
and leukemia patients. Nevertheless,
the mechanism of action of eltrombo-
pag may make it particularly suited for
applications associated with protecting
normal HSC from DNA damage, if future
studies show eltrombopag does in fact
enhance DNA repair similarly to TPO.
Studies have recently shown that eltrom-
bopag works through both mpl-depen-
dent and mpl-independent mechanisms,
and eltrombopag additionally exhibits
significant antileukemia effects (Kalota
and Gewirtz, 2010; Roth et al., 2012; Su-
gita et al., 2012). These properties are
especially desirable if eltrombopag were
to be utilized during induction chemo-
therapy and were able to impart protec-
tive effects in normal HSC while exerting
antileukemia effects on malignant cells.
Specific blood cell growth factors, such
as erythropoietin for red cells and granu-
locyte colony-stimulating factor for granu-
locytes, have shown impressive clinical
benefits. It seems that we now have a
method to expand primitive HSCs with
the ability to replenish all blood cell types.
TPO agonists, as critical factors to pro-Cell Stem Celmote ‘‘healthy’’ HSCs, show great
promise for treating hematopoietic dis-
orders caused by damaged HSCs, and
protecting HSCs in patients receiving
DNA-damaging therapy. As with these
other cytokine regimens, however, it will
be critical to determine the specific sig-
naling cascades downstream in order to
enhance the desirable outcomes while
minimizing any unwanted effects of
receptor activation.REFERENCES
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